Form 4 for RMD ResMed|
Accepted 2024-06-10 00:00:00 ET · period of report 2024-06-07 · accession 0001127602-24-018325 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-10 | 2024-06-07 | RMD | Farrell Michael J. | CEO | S - Sale+OE | $211.66 | -14.7K | 440.8K | -3% | -$3.11M |
| D | 2024-06-10 | 2024-06-07 | RMD | Farrell Michael J. | CEO | M - OptEx | $84.98 | +14.7K | 455.5K | +3% | +$1.25M |
| D | 2024-06-10 | 2024-06-07 | RMD | Farrell Michael J. | CEO | M - OptEx | $0.00 | -14.7K | 73.4K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | ResMed Common Stock | 2024-06-07 | S | D | 14,683 | $211.66 | 440,799 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $210.58 - $213.86. The price reported above reflects the weighted average sale price. (F3) Includes 46.9596 shares of ResMed stock purchased on April 30, 2024, through the ResMed Employee Stock Purchase Plan. |
| 2 | Common | ResMed Common Stock | 2024-06-07 | M | A | 14,683 | $84.98 | 455,482 | D | — | — | |
| 3 | Derivative | ResMed Common Stock Options | 2024-06-07 | M | D | 14,683 | $0.00 | 73,415 | D | $84.98 · 2018-11-11 to 2024-11-16 | 14,683 ResMed Common Stock | (F4) Represents date options first became exercisable. Options vest 1/3 per year. |